Company intelligence / Profile preview

Elan Dermatics

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Elan Dermatics is a biotechnology company focused on developing innovative topical therapies for inflammatory skin conditions. The company's primary research efforts center on the development of novel Phosphodiesterase 4 (PDE4) inhibitors designed to treat diseases such as atopic dermatitis and psoriasis with improved efficacy and safety profiles. By leveraging specialized drug delivery technologies, Elan Dermatics aims to provide targeted relief for patients suffering from chronic dermatological disorders. The company is currently advancing its lead candidates through pre-clinical development stages.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Elan Dermatics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elan Dermatics.

Explore the full profile